Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/
Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally.
AI Fairness enhances Financial Security
Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities.
The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI conferences, challenged participants to develop AI models that not only achieve high-utility performance but also demonstrate fairness across demographic subgroups such as gender, age, and skin tone. Ant International emerged first among over 2,100 submissions from 162 teams across the world at the competition. These teams were tasked to detect 1.2 million AI-generated face pictures of humans from different demographic groups.
By combining a Mixture of Experts (MoE) architecture with an internal "bias-detection" mechanism, Ant International's winning AI model trains competing neural sub-networks – one focused on spotting deepfakes, the other actively challenging it to ignore sensitive traits. This dynamic ensures the system learns to detect only genuine signs of manipulation, not demographic patterns. Trained on globally representative data including real-world payment fraud scenarios, the model delivers robust and equitable performance at scale.
“A biased AI is an insecure AI,” said Dr. Tianyi Zhang, General Manager of Risk Management and Cybersecurity at Ant International. “Our model’s fairness prevents exploitation from deepfakes and ensures reliable identity verification for all users, supporting our mission to deliver secure and inclusive financial services worldwide.”
Applications in Financial Services
Ant International is integrating the NeurIPS-winning technology directly into its payment and financial services to counter deepfake threats and ensure consistent customer experience globally.
- Account protection against deepfake attacks: Ant International’s AI-powered anti-deepfake measures have achieved a detection rate exceeding 99.8%. By prioritising fairness, this ensures robust and consistent protection against sophisticated threats like account takeovers for all demographics across 200 markets worldwide.
- Enhanced compliance for eKYC processes: The company, as well as its financial institution and merchant partners, can leverage the technology to meet stringent global Electronic Know Your Customer (eKYC) standards in customer onboarding across different markets, without introducing algorithmic bias.
- Advancing financial inclusion in emerging markets: The development of equitable and accurate AI helps ensure that Ant International can extend services to a broader, more diverse market globally, fostering greater financial inclusion.
Full-cycle security strategy to protect financial transactions
Ant International alongside its partners serve over 150 million merchants and 1.8 billion user accounts worldwide. These services include global wallet gateway Alipay+, merchant payment services Antom, inclusive finance and credit tech services Bettr and global account services WorldFirst.
Ant International has positioned AI security at the core of its operations. It has introduced the AI SHIELD, as a comprehensive, full-lifecycle foundational framework for risk management. Built on the AI Security Docker, this solution reduces risk of AI service vulnerabilities such as unauthorised access and data leakage by 90% through advanced assessment methods and running safeguards.
Risk-management solutions secured by AI SHIELD provide full-lifecycle protection of transactions at Ant International. These solutions protect businesses and users from deepfake attacks, frauds and scams. For instance, account protection solution Alipay+ EasySafePay 360 can reduce account takeover incidence for digital wallet payments by 90%.
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20251207210856/en/
Contacts
For media enquiries, please contact
Ant International Global Communications
pr@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom